Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions

被引:108
作者
Gerlini, G
Tun-Kyi, A
Dudli, C
Burg, G
Pimpinelli, N
Nestle, FO
机构
[1] Univ Zurich, Sch Med, Dept Dermatol, CH-8091 Zurich, Switzerland
[2] Univ Florence, Sch Med, Dept Dermatol Sci, Florence, Italy
关键词
D O I
10.1016/S0002-9440(10)63238-5
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
CD1 molecules are expressed by antigen-presenting cells such as dendritic cells and mediate primary immune responses to lipids and glycolipids; which have been shown to be expressed by various tumors. Glycolipids are expressed by melanoma cells but, despite their immunogenicity, no efficient spontaneous immune responses are elicited. As IL-10 has previously been shown to down-regulate CD1a on dendritic cells and is known to be expressed by various melanoma cell lines, we investigated if melanoma-derived IL-10 could down-regulate CD1 molecule expression on dendritic cells as a possible way to circumvent immune recognition. We found that CD1a, CD1b, CD1c, and CD1d were significantly down-regulated on dendritic cells in metastatic (n = 10) but not in primary melanoma lesions (n = 10). We further detected significantly higher IL-10 protein levels in metastatic than in primary melanomas. Moreover, supernatants from metastatic melanomas were significantly more effective in down-regulating CD1 molecules on dendritic cells than supernatants from primary melanoma cultures. This effect was blocked using a neutralizing IL-10 antibody in a dose dependent manner. Our findings suggest that metastatic but not primary melanomas can down-regulate CD1 molecules on infiltrating dendritic cells by secreting IL-10 which may represent a novel way to escape the immune response directed against the tumor.
引用
收藏
页码:1853 / 1863
页数:11
相关论文
共 75 条
[41]  
Livingston P, 1998, SEMIN ONCOL, V25, P636
[42]   VACCINES CONTAINING PURIFIED GM2 GANGLIOSIDE ELICIT GM2 ANTIBODIES IN MELANOMA PATIENTS [J].
LIVINGSTON, PO ;
NATOLI, EJ ;
CALVES, MJ ;
STOCKERT, E ;
OETTGEN, HF ;
OLD, LJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (09) :2911-2915
[43]   IMPROVED SURVIVAL IN STAGE-III MELANOMA PATIENTS WITH GM2 ANTIBODIES - A RANDOMIZED TRIAL OF ADJUVANT VACCINATION WITH GM2 GANGLIOSIDE [J].
LIVINGSTON, PO ;
WONG, GYC ;
ADLURI, S ;
TAO, Y ;
PADAVAN, M ;
PARENTE, R ;
HANLON, C ;
CALVES, MJ ;
HELLING, F ;
RITTER, G ;
OETTGEN, HF ;
LLOYD, JO .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (05) :1036-1044
[44]   Carbohydrate vaccines that induce antibodies against cancer .2. Previous experience and future plans [J].
Livingston, PO ;
Ragupathi, G .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1997, 45 (01) :10-19
[45]  
LIVINGSTON PO, 1989, CANCER RES, V49, P7045
[46]   Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma [J].
Nemunaitis, J ;
Fong, T ;
Shabe, P ;
Martineau, D ;
Ando, D .
CANCER INVESTIGATION, 2001, 19 (03) :239-247
[47]  
Nestle FO, 1997, AM J PATHOL, V150, P641
[48]   Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells [J].
Nestle, FO ;
Alijagic, S ;
Gilliet, M ;
Sun, YS ;
Grabbe, S ;
Dummer, R ;
Burg, G ;
Schadendorf, D .
NATURE MEDICINE, 1998, 4 (03) :328-332
[49]   CD1B RESTRICTS THE RESPONSE OF HUMAN CD4-8- LYMPHOCYTES-T TO A MICROBIAL ANTIGEN [J].
PORCELLI, S ;
MORITA, CT ;
BRENNER, MB .
NATURE, 1992, 360 (6404) :593-597
[50]   The CD1 family of lipid antigen-presenting molecules [J].
Porcelli, SA ;
Segelke, BW ;
Sugita, M ;
Wilson, IA ;
Brenner, MB .
IMMUNOLOGY TODAY, 1998, 19 (08) :362-368